Aurobindo Pharma posted an 8.6 per cent increase in net profit for the second quarter of fiscal year 2025, reaching Rs 817 crore, up from Rs 752 crore in the same period last year. The growth was primarily fueled by robust sales in its Europe and growth markets. However, the company experienced an 11 per cent decline in net profit on a quarter-on-quarter basis, reflecting some transient business factors
Read More
